Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.76M Sell
8,106
-216
-3% -$47.9K 0.68% 43
2025
Q4
$1.9M Sell
8,322
-550
-6% -$125K 0.71% 39
2025
Q3
$2.05M Buy
8,872
+809
+10% +$165K 0.74% 35
2025
Q2
$1.5M Buy
8,063
+172
+2% +$32K 0.68% 42
2025
Q1
$1.65M Sell
7,891
-825
-9% -$160K 1% 31
2024
Q4
$1.55M Buy
8,716
+272
+3% +$50K 0.94% 27
2024
Q3
$1.67M Buy
+8,444
New +$1.58M 1.04% 26

Other funds holding ABBV

Quartz Partners's ABBV Position: Q1 2026 in Review

Quartz Partners reduced its AbbVie (ABBV) stake by 2.6% in Q1 2026, selling an estimated $47.9K and leaving 8,106 shares worth $1.76M. The position accounts for 0.68% of the portfolio, ranked #43.

Quartz Partners first reported a position in ABBV in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.05M in Q3 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Quartz Partners held 8,106 shares of AbbVie worth $1.76M as of Q1 2026.
  • Quartz Partners sold 216 AbbVie shares in Q1 2026, an estimated $47.9K.
  • AbbVie made up 0.68% of Quartz Partners's portfolio in Q1 2026, its #43 holding.
  • Quartz Partners first reported a position in AbbVie in Q3 2024 and has held it in 7 quarters since.
  • Quartz Partners's AbbVie position peaked at $2.05M in Q3 2025.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Quartz Partners's 13F filing for Q1 2026, filed 5 May 2026.